WO2000002523A3 - Vaccine against staphylococcus intoxication - Google Patents

Vaccine against staphylococcus intoxication Download PDF

Info

Publication number
WO2000002523A3
WO2000002523A3 PCT/US1999/015569 US9915569W WO0002523A3 WO 2000002523 A3 WO2000002523 A3 WO 2000002523A3 US 9915569 W US9915569 W US 9915569W WO 0002523 A3 WO0002523 A3 WO 0002523A3
Authority
WO
WIPO (PCT)
Prior art keywords
intoxication
vaccine against
against staphylococcus
aureus
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015569
Other languages
French (fr)
Other versions
WO2000002523A2 (en
WO2000002523A9 (en
Inventor
John S Lee
Peter Pushko
Jonathan F Smith
Robert G Ulrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research Institute of Infectious Diseases
Original Assignee
US Army Medical Research Institute of Infectious Diseases
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research Institute of Infectious Diseases filed Critical US Army Medical Research Institute of Infectious Diseases
Priority to DE69941454T priority Critical patent/DE69941454D1/en
Priority to AT99943610T priority patent/ATE443768T1/en
Priority to AU56673/99A priority patent/AU761021B2/en
Priority to CA002337966A priority patent/CA2337966A1/en
Priority to EP99943610A priority patent/EP1097213B1/en
Publication of WO2000002523A2 publication Critical patent/WO2000002523A2/en
Publication of WO2000002523A9 publication Critical patent/WO2000002523A9/en
Publication of WO2000002523A3 publication Critical patent/WO2000002523A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Using nucleic acids encoding non-toxic mutant SEA and SEB exotoxins from Staphylococcus aureus, compositions and methods for use in inducing an immune response which is protective against staphylococcal aureus intoxication in subjects is described.
PCT/US1999/015569 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication Ceased WO2000002523A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE69941454T DE69941454D1 (en) 1998-07-10 1999-07-09 VACCINE AGAINST STAPHYLOKOKEN POISONING
AT99943610T ATE443768T1 (en) 1998-07-10 1999-07-09 VACCINE AGAINST STAPHYLOCOCCO POISONING
AU56673/99A AU761021B2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication
CA002337966A CA2337966A1 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication
EP99943610A EP1097213B1 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
US60/092,416 1998-07-10

Publications (3)

Publication Number Publication Date
WO2000002523A2 WO2000002523A2 (en) 2000-01-20
WO2000002523A9 WO2000002523A9 (en) 2000-07-27
WO2000002523A3 true WO2000002523A3 (en) 2000-11-23

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015568 Ceased WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine
PCT/US1999/015569 Ceased WO2000002523A2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015568 Ceased WO2000002522A2 (en) 1998-07-10 1999-07-09 Anthrax vaccine

Country Status (7)

Country Link
US (2) US6632640B1 (en)
EP (2) EP1097213B1 (en)
AT (2) ATE443768T1 (en)
AU (2) AU758019B2 (en)
CA (2) CA2337966A1 (en)
DE (2) DE69940157D1 (en)
WO (2) WO2000002522A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) * 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
DE69940157D1 (en) 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
CA2338184A1 (en) * 1998-08-13 2000-02-24 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
AU4238900A (en) 1999-04-16 2000-11-02 Johnson & Johnson Consumer Companies, Inc. Drug delivery device comprising a dual chamber reservoir
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (en) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2003048390A1 (en) * 2001-12-05 2003-06-12 Rakesh Bhatnagar A process for the preparation of a non-toxic anthrax vaccine
AU2003224265A1 (en) * 2002-04-11 2003-10-27 Powderject Research Limited Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
EP1575505A4 (en) * 2002-09-10 2007-01-24 Vical Inc Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040208848A1 (en) 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
CN1791678A (en) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 Improved alphavirus replicons and helper constructs
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
DE602004021260D1 (en) * 2003-07-11 2009-07-09 Alphavax Inc CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS
EP1670505B1 (en) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna promoters and anthrax vaccines
ES2422171T3 (en) 2004-02-11 2013-09-09 Ligocyte Pharmaceuticals Inc Anthrax antigens and use procedures
KR20070058631A (en) 2004-09-22 2007-06-08 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic Compositions
KR20080052509A (en) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 Vaccines Against Pandemic Flu Virus
CN101252932B (en) 2005-09-09 2012-10-03 安吉利尼莱博法姆有限责任公司 Trazodone composition for once a day administration
DK1940467T3 (en) 2005-09-09 2017-02-13 Paladin Labs Inc Long-release drug composition
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2341929B1 (en) 2008-10-06 2017-01-25 University Of Chicago Compositions and methods related to bacterial emp proteins
ES2784957T3 (en) 2009-04-03 2020-10-02 Univ Chicago Compositions and methods related to variants of protein A (SPA)
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (en) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ Compositions and methods relating to protein A (SpA) antibodies as enhancers of immune responses
JP6002128B2 (en) 2010-07-02 2016-10-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ Compositions and methods related to protein A (SpA) variants
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
US9789176B2 (en) * 2011-03-16 2017-10-17 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112014003315A2 (en) 2011-08-15 2017-03-01 Univ Chicago antibody-related compositions and methods for staphylococcal protein
AU2013252883B2 (en) 2012-04-26 2018-05-17 University Of Chicago Staphylococcal coagulase antigens and methods of their use
EP2841101B1 (en) 2012-04-26 2019-08-07 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
PT3010535T (en) 2013-06-19 2020-07-03 Integrated Biotherapeutics Inc Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
AU2017206656B2 (en) 2016-01-10 2024-02-01 Neotx Therapeutics Ltd. Immunopotentiator enhanced superantigen mediated cancer immunotherapy
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
WO2019023341A1 (en) 2017-07-27 2019-01-31 Integrated Biotherapeutics, Inc. Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
MX2021013833A (en) 2019-05-14 2022-03-17 Univ Chicago METHODS AND COMPOSITIONS INCLUDING VARIANTS OF THE PROTEIN A OF STAPHYLOCOCCUS (SPA).
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
MX2022004061A (en) 2019-10-02 2022-07-19 Janssen Vaccines & Prevention Bv Staphylococcus peptides and methods of use.
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and preparations for treating cancer with immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
WO1996037616A1 (en) * 1995-05-23 1996-11-28 The University Of North Carolina At Chapel Hill Alphavirus rna replicon systems

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014634A1 (en) * 1992-01-28 1993-08-05 National Jewish Center For Immunology And Respiratory Medicine Protective effects of mutated superantigens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
EP1055429A4 (en) * 1998-02-15 2004-09-08 Juridical Foundation NEW PREVENTIVE / CURATIVE DRUGS FOR IMMUNOPATHY
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
CA2338184A1 (en) * 1998-08-13 2000-02-24 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
CA2354374A1 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007994A2 (en) * 1993-09-15 1995-03-23 Viagene, Inc. Recombinant alphavirus vectors
WO1996037616A1 (en) * 1995-05-23 1996-11-28 The University Of North Carolina At Chapel Hill Alphavirus rna replicon systems

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
I-M. NILSSON ET AL.,: "Protection against Staphylococcus aureus sepsis by vaccination with recombinant Staphylococcal Enterotoxin A devoid of superantigenicity", J. INFECTIOUS DISEASES, vol. 180, October 1999 (1999-10-01), pages 1370 - 1373, XP002141820 *
PUSHKO P ET AL: "Replicon-helper systems from attenuated Venezuelan Equine Encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo", VIROLOGY,US,ACADEMIC PRESS,ORLANDO, vol. 239, no. 2, 22 December 1997 (1997-12-22), pages 389 - 401, XP002123951, ISSN: 0042-6822 *
R.G. ULRICH ET AL.,: "Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules", NATURE STRUCTURAL BIOLOGY, vol. 2, no. 6, June 1995 (1995-06-01), pages 554 - 560, XP000916120 *
S. BAVARI AND R.G. ULRICH: "Engineered bacterial superantigen vaccines", TOXICON, vol. 36, September 1998 (1998-09-01), pages 1231 - 1232, XP000916192 *
S. BAVARI ET AL.,: "Engineered bacterial superantigen vaccines", VACCINES, vol. 96, 1996, pages 135 - 141, XP000916124 *
S. BAVARI ET AL.,: "Superantigen Vaccines: a comparative study of genetically attenuated receptor-binding mutantsof Staphylococcal Enterotoxin A", J. INFECT. DISEASES, vol. 174, no. 2, August 1996 (1996-08-01), pages 338 - 345, XP000916129 *
ULRICH R G ET AL: "Development of engineered vaccines effective against structurally related bacterial superantigens", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 16, no. 19, 1 November 1998 (1998-11-01), pages 1857 - 1864, XP004139018, ISSN: 0264-410X *

Also Published As

Publication number Publication date
CA2339355A1 (en) 2000-01-20
US6632640B1 (en) 2003-10-14
EP1097213B1 (en) 2009-09-23
AU5542699A (en) 2000-02-01
US20040009183A1 (en) 2004-01-15
WO2000002523A2 (en) 2000-01-20
AU758019B2 (en) 2003-03-13
WO2000002523A9 (en) 2000-07-27
CA2337966A1 (en) 2000-01-20
ATE443768T1 (en) 2009-10-15
WO2000002522A3 (en) 2000-10-12
US7374931B2 (en) 2008-05-20
DE69941454D1 (en) 2009-11-05
EP1097212A2 (en) 2001-05-09
AU761021B2 (en) 2003-05-29
EP1097212B1 (en) 2008-12-24
WO2000002522A2 (en) 2000-01-20
ATE418612T1 (en) 2009-01-15
AU5667399A (en) 2000-02-01
WO2000002522A9 (en) 2001-04-05
DE69940157D1 (en) 2009-02-05
EP1097213A2 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
WO2000002523A3 (en) Vaccine against staphylococcus intoxication
WO1999051748A3 (en) Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
WO2002007742A3 (en) Bacteriophage having multiple host range
WO2005032582A8 (en) Immunogenic compositions for streptococcus pyogenes
MX9801638A (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis.
WO2000002524A3 (en) Botulinum neurotoxin vaccine
SI1542732T1 (en) Fusion proteins of mycobacterium tuberculosis
AU2003223497A1 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
AU2002345653A1 (en) Diagnostic device, system and method
WO2003051392A3 (en) Streptococcus pneumoniae vaccine
BRPI9700768B8 (en) live vaccine to fight streptococcus infection in horses.
EP2275120A3 (en) Protein-based streptococcus pneumoniae vaccines
AU1757601A (en) Cross-protective salmonella vaccines containing an avirulent salmonella choleraesuis strain
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2002034773A3 (en) Streptococcal genes
AU7105598A (en) Attenuated, invasive vaccines against fish pathogens
WO2002024739A3 (en) Spas-1 cancer antigen
WO2000061724A3 (en) Anti-bacterial vaccine compositions
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
AU2001264217A1 (en) Program execution system, program execution device, relay device, and recording medium
AU2001239296A1 (en) Method for obtaining polyhydroxyalkanoates (pha) or the copolymers thereof
AU2001251162A1 (en) Hair conditioning composition comprising vinylpyrrolidone copolymer
WO2003093416A3 (en) Protective antigens for the control of ixodes species infestations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; PAGES 1-3, SEQUENCE LISTING, REPLACED BY NEW PAGES 1-3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2337966

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999943610

Country of ref document: EP

Ref document number: 56673/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999943610

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 56673/99

Country of ref document: AU